ImpediMed Past Earnings Performance

Past criteria checks 0/6

ImpediMed has been growing earnings at an average annual rate of 3.2%, while the Medical Equipment industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 16.8% per year.

Key information

3.2%

Earnings growth rate

43.7%

EPS growth rate

Medical Equipment Industry Growth8.9%
Revenue growth rate16.8%
Return on equity-48.6%
Net Margin-191.8%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How ImpediMed makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OTCPK:IPDQ.F Revenue, expenses and earnings (AUD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2410-20260
31 Mar 2410-20260
31 Dec 2310-19260
30 Sep 2311-20260
30 Jun 2311-21251
31 Mar 2311-21261
31 Dec 2211-22261
30 Sep 2211-21251
30 Jun 2211-20241
31 Mar 2210-20231
31 Dec 2110-19231
30 Sep 219-20241
30 Jun 218-21251
31 Mar 217-20232
31 Dec 206-19222
30 Sep 206-20223
30 Jun 206-21223
31 Dec 195-25243
30 Sep 195-24233
30 Jun 194-24233
31 Dec 184-25263
30 Sep 183-26283
30 Jun 183-27303
31 Mar 184-28303
31 Dec 174-28304
30 Sep 175-28305
30 Jun 176-28295
31 Mar 176-28306
31 Dec 166-29316
30 Sep 166-27305
30 Jun 166-26284
31 Mar 166-23253
31 Dec 155-20222
30 Sep 155-17202
30 Jun 155-15171
31 Mar 154-13151
31 Dec 144-10130
30 Sep 144-9120
30 Jun 144-8100
31 Mar 143-7100

Quality Earnings: IPDQ.F is currently unprofitable.

Growing Profit Margin: IPDQ.F is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: IPDQ.F is unprofitable, but has reduced losses over the past 5 years at a rate of 3.2% per year.

Accelerating Growth: Unable to compare IPDQ.F's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IPDQ.F is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (15%).


Return on Equity

High ROE: IPDQ.F has a negative Return on Equity (-48.57%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 17:36
End of Day Share Price 2024/12/17 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

ImpediMed Limited is covered by 9 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Dennis HulmeAPP Securities Pty Ltd.
Russell WrightBarclay Pearce Capital Pty Limited
Matthijs SmithCanaccord Genuity